Exploring Tunable Hyperparameters for Deep Neural Networks with Industrial ADME Data Sets
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Deep learning has drawn significant attention in different areas including drug discovery. It has been proposed that it could outperform other machine learning algorithms, especially with big data sets. In the field of pharmaceutical industry, machine learning models are built to understand quantitative structure-activity relationships (QSARs) and predict molecular activities, including absorption, distribution, metabolism, and excretion (ADME) properties, using only molecular structures. Previous reports have demonstrated the advantages of using deep neural networks (DNNs) for QSAR modeling. One of the challenges while building DNN models is identifying the hyperparameters that lead to better generalization of the models. In this study, we investigated several tunable hyperparameters of deep neural network models on 24 industrial ADME data sets. We analyzed the sensitivity and influence of five different hyperparameters including the learning rate, weight decay for L2 regularization, dropout rate, activation function, and the use of batch normalization. This paper focuses on strategies and practices for DNN model building. Further, the optimized model for each data set was built and compared with the benchmark models used in production. Based on our benchmarking results, we propose several practices for building DNN QSAR models.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Exploring Tunable Hyperparameters for Deep Neural Networks with Industrial ADME Data Sets
- Date Crossref
- 26/12/2018
- Éditeur
- American Chemical Society (ACS)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Eli Lilly (United States) pays non établi dans la noticeEntreprise
-
Ohio University Department of Chemistry and Biochemistry pays non établi dans la noticeUniversité ou école supérieure
-
Eli Lilly and Company Drug Disposition pays non établi dans la noticeEntreprise
Eli Lilly (United States), Department of Chemistry and Biochemistry — Ohio University et Drug Disposition — Eli Lilly and Company.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.